Vaxart (VXRT) announced that it will present research featuring its COVID-19 and norovirus oral pill vaccine candidates at the World Vaccine ...
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: VXRT) today announced that it will present research featuring its COVID-19 and norovirus oral pill vaccine candidates at the ...
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it will present research featuring its COVID-19 and norovirus oral pill vaccine ...
On Monday, Vaxart Inc (VXRT) stock saw a decline, ending the day at $0.78 which represents a decrease of $-0.04 or -4.88% from the prior close of $0.82. The stock opened at $0.81 and touched a low of ...
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it will present research featuring its COVID-19 and norovirus oral pill vaccine ...
MedPage Today on MSN3d
Are Norovirus Vaccines on the Horizon?The first, an investigational norovirus mRNA vaccine from Moderna (mRNA-1403), safely elicited strong antibody responses in ...
A vaccine is to be trialled on thousands of people to find out if it could protect against norovirus - a stomach bug that ...
A new trial that aims to protect against norovirus, a highly contagious stomach bug that causes vomiting and diarrhoea, is ...
At IDWeek 2024, Moderna presented interim results from an ongoing Phase I/II dose-ranging trial for mRNA-1403, a vaccine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback